As new agents like T-DXd and tucatinib enter the early HER2+ setting, where does Neratinib fit? Drs. Mouabbi, Kang, and Birhiray weigh its enduring value in brain protection and tolerability.
Neratinib’s Future: What is its Role in the Evolving Early HER2+ Landscape?
You may also like
Recommended Videos
